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Abstract
Purpose of Review Peripheral arterial disease (PAD) is the third most common manifestation of cardiovascular disease (CVD),
following coronary artery disease (CAD) and stroke. PAD remains underdiagnosed and under-treated in women.
Recent Findings Women with PAD experience more atypical symptoms and poorer overall health status. The prevalence of PAD in
women increases with age, such that more women than men have PAD after the age of 40 years. There is under-representation of
PAD patients in clinical trials in general and women in particular. In this article, we address the lack of women participants in PAD
trials. We then present a comprehensive overview of the epidemiology/risk factor profile, clinical features, treatment, and outcomes.
Summary PAD is prevalent in women and its global burden is on the rise despite a decline in global age-standardized death rate
from CVD. The importance of this issue has been underlined by the American Heart Association’s (AHA) “Call to Action”
scientific statement on PAD in women. Large-scale campaigns are needed to increase awareness among physicians and the
general public. Furthermore, effective treatment strategies must be implemented.
Keywords Peripheral arterial disease . Women . Sex differences
Background
Peripheral arterial disease (PAD) remains a significant health
concern across the globe. As of 2010, more than 200 million
people worldwide are living with PAD, representing a 29%
increased prevalence in low-middle income countries and
13% increase in high income countries [1, 2]. In the USA
alone, PAD affects 8 million Americans aged > 40 years [3].
In the Reduction of Atherothrombosis for Continued Health
(REACH) Registry, the cumulative end point of major cardio-
vascular events, vascular interventions, and hospitalization
was significantly higher in patients with PAD than patients
with coronary artery disease (CAD) [4]. PAD is associated
with equal morbidity and mortality and economic costs as
CAD and ischemic stroke [5, 6]. In a scientific statement on
Women and PAD from the AHA in 2012 [7], Hirsch et al.
noted the increased prevalence of PAD in adults ≥ 40 years
of age, and highlighted the need for raising clinical awareness,
focused treatment plans, and expanding research on PAD in
women. Women have higher rates of asymptomatic/
subclinical disease and the majority have atypical symptoms.
They also have a poorer overall health status. Women with
PAD suffer more from depression compared to women with-
out PAD [8–15, 16•].
Overall, there is limited recruitment of patients with PAD in
cardiovascular trials, especially women, minorities, and the
elderly [17•]. For the purpose of this review, we will focus
on the different aspects of PAD in women including data on
representation in research studies, epidemiology, clinical fea-
tures, and outcomes.
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Representation of Women in PAD Studies
Sex differences in PAD have been reported not only in prev-
alence, diagnosis, and clinical presentation but also in out-
comes. Women continue to have variable enrollment in stud-
ies on PAD (Table 1 and Fig. 1). In more than half of these
studies, women comprise < 35% of the whole study popula-
tion. In the Nation Wide inpatient sample of patients with
PAD, women comprised 41% of the study population.
However, in randomized control trials (RCT) of vascular sur-
gery, women represented only 22% [18]. In a systematic re-
view of cardiovascular trials, which collectively enrolled
412,048 patients, only 27% of the total population were wom-
en [17•]. While enrollment of women has increased overall in
clinical trials, it continues to lag behind their overall represen-
tation in this disease [19•].
Epidemiology and Risk Factors
Women with PAD present on average 10–20 years later than
men [20]. Around 20–30% of women aged 70 years or older
are affected by PAD [21, 22]. This is hypothesized to be sec-
ondary to the loss of the vascular protective effects of estrogen
which promotes vasodilation and has anti-oxidative effects. In
a study of > 370,000 surgical inpatients with PAD, Vouyouka
et al. found that women were more likely to be older, obese,
and black [23•]. Overall risk factors for PAD remain similar
among men and women, including smoking, age, diabetes
mellitus, hypertension, and dyslipidemia [3]. Diabetes and
hyperlipidemia have been shown to increase the risk of inter-
mittent claudication by fourfold in women [24, 25].
Importantly, ethnic differences have been shown to affect the
prevalence of PAD as well, with the highest prevalence of
PAD among non-Hispanic black women over the age of 70
(25%) [26•]. Other studies have shown association between
obesity [27], levels of C-reactive protein (CRP) [28, 29],
osteopenia/osteoporosis [30, 31], hypothyroidism, and PAD.
In the Multiethnic Study of Atherosclerosis (MESA) [29],
women had higher levels of CRP than men, after adjustment
for comorbidities, hormonal status, and age. Conflicting data
has emerged for the association between hormone replace-
ment therapy and PAD in women. In the Women Health
Initiative (WHI) and Heart and Estrogen/Progestin replace-
ment (HERS) studies, no benefit was observed from HRT
use for PAD or CAD. Conversely, the Rotterdam study
showed a 52% decreased risk of PAD in women who used
HRT for > 1 year [32–34]. Interestingly, vascular complica-
tions associated with pregnancy have also been associated
with an increased risk of PAD. The Cardiovascular Health
After Maternal Placental Syndrome (CHAMPS) study
showed a threefold increased risk of PAD and twofold in-
creased risk of coronary artery and cerebrovascular disease
in patients with maternal placental syndromes, including
pre-eclampsia, gestational hypertension, placental abruption,
and placental infarction [35]. The mechanisms for this associ-
ation are unclear, although one likely hypothesis is underlying
endothelial dysfunction.
The treatment of risk factors varies by gender. In the
REACH registry [4], consisting of > 68,000 outpatients, risk
factor control was less frequently observed in patients with
diagnosis of PAD. Optimal risk factor control was twice as
likely for men than women despite a higher incidence of dia-
betes, hypertension, and elevated total cholesterol in women.
Symptoms
Both men and women present with typical, atypical, or
asymptomatic PAD. Studies have shown that the majority of
PAD patients do not have typical claudication [11, 36].
Asymptomatic disease is defined as absence of exertional
leg symptoms in the presence of an ankle-brachial index
(ABI) < 0.90, while atypical symptoms are defined by leg
symptoms present at rest and exercise [37, 38]. In the
Women Health and Aging study (WHAS), of the 933 women
enrolled, 35% (n = 328) had an ABI of 0.90; of these, 328
patients (63%) had no exertional leg symptoms [39].
Importantly, asymptomatic PAD has been shown to be more
common in women than in men (13 vs 9%; p < 0.03) [40].
When symptomatic, women seek medical attention with more
complex (multilevel) and severe disease including critical
limb ischemia (CLI) [16•, 40, 41]. In patients with CLI, wom-
en had a twofold higher incidence of femoropopliteal disease
compared tomen [42]. This finding was reproduced in another
patient cohort undergoing angioplasty that showed pro-
nounced femoropopliteal disease in women while men had
more below-the-knee disease [43]. Additionally, women have
greater lower extremity functional impairment [8], with
shorter treadmill distance to intermittent claudication [44],
shorter maximal treadmill walking distance [8, 44], and poorer
quality of life scores compared to men [45]. Other studies
have demonstrated a higher prevalence of asymptomatic dis-
ease in women, which may lead to a late presentation, thus
contributing to severe disease or CLI [41].
Treatment
The principle components of PAD treatment consist of super-
vised exercise therapy, pharmacological treatment, and lower
extremity revascularization. Patients with PAD are less likely to
receive guideline-directed medical therapy (GDMT) than are
patients with other forms of cardiovascular disease, including
CAD [46–48]. For example, in one study on secondary preven-
tion of PAD, statin use was reported in only 31%, angiotensin-
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converting enzyme inhibitor use in 25%, and aspirin use in 36%
[48]. Data also exists on suboptimal use of systemic vascular
treatment or lack of adherence to standard therapy. In the
NHANES study, only 24–34% adherence to preventive therapy
was reported [48]. CHAMPS study cited similar suboptimal use
of GDMTbutwas particularly notable for lower rates in women
and older patients [31]. In terms of intensity of treatment with
standard pharmacologic agents, men were more likely to re-
ceive all agents (antiplatelets, statins, and angiotensin enzyme
inhibitors) than women (22.4 vs 18.2%) [31]. This finding was
reproduced in another study from Quebec which showed that
men were more likely to receive statins, antiplatelet agents, and
angiotensin-converting enzyme inhibitors than women (22.4 vs
18.2%, p < 0.001) [31].
Patients with PAD experience a profound limitation in ex-
ercise performance. There is evidence of a well-established
benefit following a typical 12-week exercise training program
[49, 50]. Lower extremity exercise training has been shown to
increase time to claudication, increase distance before claudi-
cation, and increase overall walking distance [51].
Unfortunately, women with PAD have been shown to be less
responsive to exercise rehabilitation programs [52], particular-
ly diabetic women. This may partly be due to a greater im-
pairment in calf muscle oxygen saturation during and follow-
ing exercise [53]. Gardner et al. reported that improvements in
absolute walking distance were significantly less for women
than men after 1 year of standard exercise therapy. Women
also reported less subjective improvement on walking impair-
ment questionnaire domains [54]. These differences have been
attributed to lower hemoglobin saturation during ambulation
[53], poorer leg strength [55], higher inflammation, higher
level of oxidative stress, and insulin resistance [53].
Endovascular revascularization and open bypass surgery
are two strategies for disabling claudication after failure of
medical therapy or for those with CLI. Although the choice
of procedure depends on many lesion characteristics includ-
ing lesion site [56, 57], the 2016 AHA/ACC Guidelines
recommend an endovascular approach first for both lifestyle
limiting claudication and CLI. While data has been equivo-
cal, sex differences have also been reported in lower extrem-
ity endovascular versus bypass treatment. Using 69 million
discharge records from the Nationwide Inpatient Sample
from 1998 to 2006, Roe et al. reported discrepancies in the
proportion of endovascular procedures being performed in
women compared to men. Women were less likely to under-
go amputation or open vascular surgery than men. Women,
however, were more likely to undergo an endovascular pro-
cedure during hospitalization [58, 59]. Several possible rea-
sons have been cited for lower bypass rates, including the
observation that women with PAD are generally older with
more advanced disease, comorbidities, and may have small-
er vessel size precluding bypass.
Carotid Artery Stenosis and Management
Women have a greater risk of disabling stroke (58 vs 48%)
and stroke-related mortality (20 vs 14%) [60]. Stroke-
related mortality has not changed over the past 50 years in
women and is attributed to older age at onset of stroke
among women [60]. Multiple trials have demonstrated a
reduction in the risk of stroke in select patients with symp-
tomatic internal carotid artery disease and to a lesser extent,
in those with asymptomatic carotid artery disease [61–63].
However, it is noteworthy that women comprised only 28–
34% of enrolled patients in these trials. In an analysis of the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) and ACAS trial, 30-day risk for death
was higher in women than in men (2.3 vs 0.8%, p =
0.002), owing to higher risk of fatal stroke [64]. Both men
and women benefited from carotid endarterectomy (CEA)
for stroke prevention. However, in another study, the risk of
stroke or death within 30 days after CEA in symptomatic
patients was greater in women (8.7%) vs men (6.8%) [65], a
Fig. 1 Trends and % women in
cardiovascular clinical trials
1994–2017
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finding which was reproduced in a systematic review of 36
studies [66]. However, other studies have shown no signif-
icant difference in complications and mortality following
CEA [67, 68]. Regarding carotid artery stenting, women
have worse outcomes, including higher rates of in-hospital
mortality and stroke [69]. Risk of stroke or mortality was
1.7-fold higher in symptomatic women and 3.4-fold higher
in asymptomatic women with carotid artery stenosis (CAS)
compared to CEA. Asymptomatic women experienced
worse outcomes compared to men, with higher stroke rates
after CEA and higher myocardial infarction rates after both
CEA and CAS [70].
Quality of Life
Quality of life scores have become an important tool to assess
treatment effectiveness in the general population.Multiple stud-
ies have shown worse health status and health-related quality of
life in women when compared with men suffering from PAD
[10, 12, 13]. In addition, functional status has been determined
to be significantly lower for women [45]. This was associated
with greater mood disturbances [12]. Female gender has been
adversely associated with durability of the revascularization or
the quality of life following revascularization for claudication or
CLI [71]. In a longitudinal study of a large PAD population,
women with PAD were found to have compromised health
status both at diagnosis and 12 months after follow-up. The
mechanism for poor health status in these women was thought
to be associated with lower education and lack of social support
(women were less likely to have a partner) [72].
Outcomes/Prognosis
Outcome trials of endovascular or surgical revascularization in
men and women have reported conflicting results. Several stud-
ies have reported an unfavorable impact of sex on outcomes
after peripheral revascularization procedures Women tend to
have higher perioperative mortality whether undergoing surgi-
cal or endovascular procedures [73, 74]. Furthermore, they
have inferior patency rates after surgical revascularization
[75–77], higher risk of stent thrombosis with endovascular re-
vascularization [77], wound complications [78], and bleeding
events [23•]. On the other hand, multiple other studies, includ-
ing some systematic reviews, have found no sex difference in
patency rates and amputation-free survival [79–81].
PAD is associated with increased risk of CVD mortality
and morbidity. A low ABI (≤ 0.9) is associated with a three-
fold increased risk of all-cause mortality and cardiovascular
mortality in both men and women [82]. Women with PAD
have a two- to fourfold increased risk of cardiovascular mor-
tality and morbidity compared to women without PAD [15].
Compared to men, women are more likely to be admitted for
acute myocardial infarction [83], more likely to be admitted
emergently with longer hospital stays and more likely to re-
quire rehabilitation or nursing home care [16•, 59, 84].
Similarly, women with CLI have higher in-hospital mortality
after both endovascular treatments and open surgery [85].
Conclusions
PAD remains a major healthcare problem. It remains
underdiagnosed and understudied in women. The major chal-
lenge in PAD treatment in women is their late presentation and
the higher prevalence of asymptomatic disease which may
lead to more advanced disease at presentation and a higher
risk of adverse events and mortality. Concerted research ef-
forts should be carried out to further determine the effects of
sex on different aspects of PAD including risk factors, clinical
burden, treatment, and outcomes. In addition, campaigns to
raise awareness among clinicians and the general public
should be undertaken. Efforts along the lines of the
“National Wear Red Day” campaign by the AHA should be
pursued aggressively to increase awareness.
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